Skip to main content
SpringerLink
Log in

Zehn Jahre Biologics in der Dermatologie

A decade of biologics in dermatology

  • Übersichten
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Fortschritte in der Pathogeneseforschung der Psoriasis haben dazu geführt, zunehmend molekulare Zielstrukturen zu identifizieren und therapeutisch zu nutzen. Waren die beiden ersten Biologics – Alefacept und Efalizumab – Entwicklungen dermatologischen Ursprungs, setzten sich parallel Zytokinantagonisten durch, bei denen überwiegend Erfahrungen in anderen Fachgebieten vorlagen (TNF-α-Antagonisten). Die klinische Nutzung der Biologics bei Psoriasis hat auf unterschiedlichen Ebenen zu Konsequenzen geführt, die ohne Biologics wahrscheinlich nicht thematisiert worden wären. Der praktische Wissenszuwachs hat vice versa Impulse für die Forschung ausgelöst, sodass gegenwärtig neue Therapiestrategien – nicht nur auf biologischer Basis – in Entwicklung sind. Jenseits der Psoriasis partizipieren zunehmend weitere Disziplinen der Dermatologie von Biologics wie Ipilimumab oder Omalizumab.

Abstract

Basic research on psoriasis has identified a number of molecular targets which can be of therapeutic interest. While the first two biologics—alefacept and efalizumab—were developed primarily for dermatologists, other agents like cytokine antagonists (TNFα antagonists) were introduced primarily by other medical fields. Knowledge has provided new impulses for research, so that today many therapeutic strategies are being developed, not exclusively limited to biologics. Others branches of dermatology also have benefitted greatly from biologics like ipilimumab or omalizumab

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011) The „psoriatic march“: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303–307

    Article  PubMed  Google Scholar 

  2. Breynaert C, Ferrante M, Fidder H et al (2011) Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 106:778–785

    Article  PubMed  CAS  Google Scholar 

  3. Braun-Falco O (1956) Beitrag zum histochemischen Nachweis von Esterasen in normaler und psoriatischer Haut. Arch Klin Exp Dermatol 202:153–162

    Article  PubMed  CAS  Google Scholar 

  4. Braun-Falco O (1997) Auf der Suche nach den Psoriasis-Genen. Hautnah 13:146–147

    Google Scholar 

  5. Collamer AN, Guerrero KT, Henning JS, Battafarano DF (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59:996–1001

    Article  PubMed  CAS  Google Scholar 

  6. Diel R, Hauer B, Loddenkemper R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 68:411–416

    Article  PubMed  CAS  Google Scholar 

  7. Dommasch ED, Abuabara K, Shin DB et al (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systemic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64:1035–1050

    Article  PubMed  CAS  Google Scholar 

  8. Gately MK, Renzetti LM, Magram J et al (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16:495–521

    Article  PubMed  CAS  Google Scholar 

  9. Genovese MC, Van den Bosch F, Roberson SA et al (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62:929–939

    Article  PubMed  CAS  Google Scholar 

  10. Gniadecki R, Kragballe K, Dam TN, Skov L (2011) Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 164:1091–1096

    Article  PubMed  CAS  Google Scholar 

  11. Günther C, Starke J, Zimmermann N, Schäkel K (2011) Human slan (6-sulfo LAcNAc) dendritic cells are a major population of dermal dendritic cells in steady state and inflammation. Clin Exp Dermatol [Epub ahead of print]

  12. Gupta MA, Gupta AK (1998) Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139:846–850

    Article  PubMed  CAS  Google Scholar 

  13. Hansel A, Günther C, Ingwersen J et al (2011) Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1T-cell responses. J Allergy Clin Immunol 127:787–94

    Article  PubMed  Google Scholar 

  14. Jojanovic DV, Di Battista JA, Martel-Pelletier J et al (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, ILβ and TNFα, by human macrophages. J Immunol 160:3513–3521

    Google Scholar 

  15. Krueger G, Koo J, Lebwohl M et al (2001) The impact of psoriasis on quality of life: results of a 1998 National Psorisis Foundation patient-membership survey. Arch Dermatol 137:280–284

    PubMed  CAS  Google Scholar 

  16. Lowes MA, Kikuchi T, Fuentes-Duculan J et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17T cells. J Invest Dermatol 128:1207–1211

    Article  PubMed  CAS  Google Scholar 

  17. Ludwig RJ, Herzog C, Rostock A et al (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271–276

    Article  PubMed  CAS  Google Scholar 

  18. Maurer M, Altrichter S, Bieber T et al (2011) Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 128(1):202–209

    Article  PubMed  CAS  Google Scholar 

  19. Mrowietz U, Kragballe K, Reich K et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–10

    Article  PubMed  CAS  Google Scholar 

  20. Nast A, Boehncke WH, Mrowietz U et al (2011) S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):1–104

    Google Scholar 

  21. Nestle FO, Conrad C (2004) The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol 123:xiv–xv

    Article  PubMed  CAS  Google Scholar 

  22. Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutics opportunities. J Clin Invest 113:1664–1675

    PubMed  CAS  Google Scholar 

  23. Oh CS, Das KM, Gottlieb AB (2000) Treatment with antitumor necrosis factor alpha monoclonal antibody dramatically decreases the clinical acivity of psoriasis lesions. J Am Acad Dermatol 42:829–830

    Article  PubMed  CAS  Google Scholar 

  24. Papp KA, Sigurgeirrson B, Abe M et al (2011) Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis. 20th Congress of the European Academy of Dermatology and Venerology (EADV) 20–24 October, 2011, Lisbon, Portugal (Abstract No. 0626)

  25. Prinz J, Braun-Falco O, Meurer M (1991) Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 338:320–321

    Article  PubMed  CAS  Google Scholar 

  26. Prodanovich S, Ma F, Taylor JR et al (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267

    Article  PubMed  Google Scholar 

  27. Rapp SR, Feldman SR, Exum ML et al (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:401–407

    Article  PubMed  CAS  Google Scholar 

  28. Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367–1374

    Article  PubMed  CAS  Google Scholar 

  29. Rich PA, Sigurgeirrson B, Thaçi DP et al (2011) Secukinumab, a new fully human monoclonal anti-interleukin-17 A antibody, in the treatment of moderate-to-severe plaque psoriasis: Interim efficacy and safety data from a phase II regimen-finding trial. 20th Congress of the European Academy of Dermatology and Venerology (EADV) 20–24 October, 2011, Lisbon, Portugal (Abstract No. 0627)

  30. Russel CB, Kerkhof K, Bigler J et al (2010) Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol 130:46

    Google Scholar 

  31. Ryan C, Leonardi CL, Krueger JG et al (2011) Association between biologic therapies for chronic plaque psoriasis and cardiovascular events. JAMA 306:864–871

    Article  PubMed  CAS  Google Scholar 

  32. Schäkel K, Kietzell M von, Hansel A et al (2006) Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 24:767–777

    Article  PubMed  Google Scholar 

  33. Schön MP (2008) Animal models of psoriasis: a critical appraisal. Exp Dermatol 17:703–712

    Article  PubMed  Google Scholar 

  34. Schmitt J, Stoller E, Wozel G (2005) Alefacept. Erfolgreiche Langzeittherapie einer schweren Psoriasis. Hautarzt 56:360–362

    Article  PubMed  CAS  Google Scholar 

  35. Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194–199

    Article  PubMed  Google Scholar 

  36. Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview (review). Cochrane Library 2:1–58

    Google Scholar 

  37. Sofen H, Smith S, Matheson R et al (2011) Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis. Br J Dermatol 165:e10

    Google Scholar 

  38. Thaçi D, Ortonne JP, Chimenti S et al (2010) A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety ofadalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 163:402–411

    Article  PubMed  Google Scholar 

  39. Wozel G, Vitez L (2008) Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol 88:169–170

    Article  PubMed  Google Scholar 

  40. Thaçi D, Daiber W, Boehncke WH, Kaufmann R (2001) Calcipotriol solution for the treatment of scalp psoriasis: Evalutation of efficacy, safety and acceptance in 3,396 patients. Dermatology 203:153–156

    Article  PubMed  Google Scholar 

  41. Rich P, Scher RK (2003) Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis J Am Acad Dermatol 49:206–212

    Google Scholar 

  42. Yoon H-S, Choi J-W, Youn J-I (2008) Method of assessing involved facial areas: rule of fours. Br J Dermatol 158:1022–1028

    Article  PubMed  Google Scholar 

  43. Krell J, Nelson C, Spencer L, Miller S (2008) An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol 58:609–616

    Article  PubMed  Google Scholar 

  44. Chen SC, Yeung J, Chren M-M (2002) Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 138:803–807

    Article  PubMed  Google Scholar 

  45. Wilson NJ, Boniface K, Chan JR et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950–957

    Article  PubMed  CAS  Google Scholar 

  46. Pappu R, Ramirez-Carrozi V, Sambandam A (2011) The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 134:8–16

    Article  PubMed  CAS  Google Scholar 

  47. Hueber W, Patel DD, Dryja T et al (2010) Effects of AIN457, a fully human antibody to interleukin-17 A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:1–9

    Article  Google Scholar 

  48. Kremer JM, Bloom BJ, Breedveld FC et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895–1905

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist für sich und seinen Koautor auf folgende Beziehungen hin: G.W. ist Mitglied in verschiedenen „advisory boards“ von Herstellern von Biologics (z. B. Pfizer, Biogen). G.W. hat Honorare für Vorträge über Biologics über alle Hersteller erhalten. Er ist in Forschungsprojekten mit der Firma Pfizer eingebunden und als LKP für klinische Studien mit Biologics tätig.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    G. Wozel

  2. Universitäts AllergieCentrum (UAC), Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland

    M. Meurer

Authors
  1. G. Wozel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Meurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Wozel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wozel, G., Meurer, M. Zehn Jahre Biologics in der Dermatologie. Hautarzt 63 (Suppl 1), 53–58 (2012). https://doi.org/10.1007/s00105-011-2296-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-011-2296-5

Schlüsselwörter

Keywords

Search

Navigation